# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...
Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melan...
Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.5...
Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing i...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...
Ladenburg Thalmann analyst Ahu Demir upgrades Evaxion Biotech (NASDAQ:EVAX) from Neutral to Buy and announces $8 price target.